{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:28:14Z","timestamp":1793532494289,"version":"4.5.0"},"reference-count":204,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmacokinetic (PK) and pharmacodynamic (PD) variability in special populations can impact antimicrobial efficacy and safety. This review highlights the importance of PK\/PD optimization in patients known to have altered PK, including those with obesity, cystic fibrosis, renal dysfunction, critical illness, transplantation, pregnancy, and\/or significant burns. Historically, PK\/PD data are underrepresented in these populations, leading to suboptimal dosing recommendations and increased risks of therapeutic failure or toxicity. Herein, we discuss key physiological alterations affecting antimicrobial PK\/PD, regulatory challenges, and currently available solutions. To bridge these knowledge gaps, we advocate for broader patient inclusion in clinical trials, improved PK modeling, real-world data collection, and increased investment in precision dosing strategies. Addressing these issues has the potential to enhance patient outcomes, reduce antimicrobial resistance, and improve infectious diseases management. This review serves as a call to action for researchers, clinicians, and policymakers to prioritize PK\/PD research in special patient populations.<\/jats:p>","DOI":"10.1093\/ofid\/ofag093","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:49:17Z","timestamp":1772023757000},"source":"Crossref","is-referenced-by-count":3,"title":["Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-458X","authenticated-orcid":false,"given":"Marguerite L","family":"Monogue","sequence":"first","affiliation":[{"name":"US Medical Affairs, bioM\u00e9rieux , Salt Lake City, Utah ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0341-0171","authenticated-orcid":false,"given":"James M","family":"Sanders","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Texas Southwestern Medical Center , Dallas, Texas ,","place":["USA"]},{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7619-8736","authenticated-orcid":false,"given":"Nicholas J","family":"Mercuro","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pharmacy, MaineHealth Maine Medical Center , Portland, Maine ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0880-1780","authenticated-orcid":false,"given":"Crystal K","family":"Hodge","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Texas Southwestern Medical Center , Dallas, Texas ,","place":["USA"]},{"name":"Department of Pharmacotherapy, University of North Texas Health Science Center , Fort Worth, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Golnabi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Texas Southwestern Medical Center , Dallas, Texas ,","place":["USA"]},{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyla","family":"Carettini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Texas Southwestern Medical Center , Dallas, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina F","family":"Yen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, MaineHealth Maine Medical Center , Portland, Maine ,","place":["USA"]},{"name":"Department of Medicine, Tufts University School of Medicine , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1359-4701","authenticated-orcid":false,"given":"James B","family":"Cutrell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2026031804265805000_ofag093-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2026031804265805000_ofag093-B2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics\u2013pharmacodynamics of antimicrobial therapy: it's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026031804265805000_ofag093-B3","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40262-020-00892-0","article-title":"Preclinical pharmacokinetic\/pharmacodynamic studies and clinical trials in the drug development process of EMA-approved antibacterial agents: a review","volume":"59","author":"Jorda","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B4","doi-asserted-by":"crossref","first-page":"888079","DOI":"10.3389\/fphar.2022.888079","article-title":"The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: a review","volume":"13","author":"Palmer","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026031804265805000_ofag093-B5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fphar.2014.00174","article-title":"Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research","volume":"5","author":"Tuntland","year":"2014","journal-title":"Front Pharmacol"},{"key":"2026031804265805000_ofag093-B6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12967-018-1710-5","article-title":"Reviewing the role of healthy volunteer studies in drug development","volume":"16","author":"Karakunnel","year":"2018","journal-title":"J Transl Med"},{"key":"2026031804265805000_ofag093-B7","doi-asserted-by":"crossref","first-page":"e0204621","DOI":"10.1128\/aac.02046-21","article-title":"Cefepime precision dosing tool: from standard to precise dose using nonparametric population pharmacokinetics","volume":"66","author":"Alshaer","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B8","volume-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products","author":"European Medicines Agency","year":"2016"},{"key":"2026031804265805000_ofag093-B9","volume-title":"Division of Pharmacometrics","author":"Center for Drug Evaluation and Research","year":"2021"},{"key":"2026031804265805000_ofag093-B10","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"2026031804265805000_ofag093-B11","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/cis270","article-title":"Excess deaths associated with tigecycline after approval based on noninferiority trials","volume":"54","author":"Prasad","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026031804265805000_ofag093-B12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/17425255.2013.788150","article-title":"Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia","volume":"9","author":"Lagac\u00e9-Wiens","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026031804265805000_ofag093-B13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1473-3099(19)30717-0","article-title":"Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia\u2014authors' reply","volume":"20","author":"Kollef","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026031804265805000_ofag093-B14","author":"Tetraphase Pharmaceuticals, Inc. Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections (cUTI)"},{"key":"2026031804265805000_ofag093-B15","author":"Clinical and Laboratory Standards Institute (CLSI)"},{"key":"2026031804265805000_ofag093-B16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/1060028016664361","article-title":"Ceftaroline as salvage monotherapy for persistent MRSA bacteremia","volume":"50","author":"Burnett","year":"2016","journal-title":"Ann Pharmacother"},{"key":"2026031804265805000_ofag093-B17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections [manuscript published online ahead of print 7 August 2024]","volume":"2024","author":"Tamma","journal-title":"Clin Infect Dis"},{"key":"2026031804265805000_ofag093-B18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.cmi.2020.04.027","article-title":"Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper","volume":"26","author":"Turnidge","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026031804265805000_ofag093-B19","doi-asserted-by":"crossref","first-page":"e02371-16","DOI":"10.1128\/AAC.02371-16","article-title":"Pharmacokinetics and pharmacodynamics of minocycline against Acinetobacter baumannii in a neutropenic murine pneumonia model","volume":"61","author":"Zhou","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"key":"2026031804265805000_ofag093-B21"},{"key":"2026031804265805000_ofag093-B22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/pharmaceutics14020445","article-title":"Prevalence and risk factors of augmented renal clearance: a systematic review and meta-analysis","volume":"14","author":"Hefny","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026031804265805000_ofag093-B23","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/978-3-540-76341-3_52","article-title":"Infectious diseases and the kidney","author":"Herberg","year":"2009","journal-title":"Pediatric Nephrology"},{"key":"2026031804265805000_ofag093-B24","volume-title":"Pharmacokinetic\/pharmacodynamic considerations for urinary tract infections","author":"Monogue"},{"key":"2026031804265805000_ofag093-B25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1751143714564816","article-title":"Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient","volume":"16","author":"Shah","year":"2015","journal-title":"J Intensive Care Soc"},{"key":"2026031804265805000_ofag093-B26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5005\/jp-journals-10071-23392","article-title":"Drug dosing in critically ill patients with acute kidney injury and on renal replacement therapy","volume":"24","author":"Saran","year":"2020","journal-title":"Indian J Crit Care Med"},{"key":"2026031804265805000_ofag093-B27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bjae.2018.09.006","article-title":"Pharmacokinetics in sepsis","volume":"19","author":"Charlton","year":"2019","journal-title":"BJA Educ"},{"key":"2026031804265805000_ofag093-B28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/bja\/aer515","article-title":"Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy","volume":"108","author":"Woodcock","year":"2012","journal-title":"Br J Anaesth"},{"key":"2026031804265805000_ofag093-B29","doi-asserted-by":"crossref","first-page":"e02584-19","DOI":"10.1128\/AAC.02584-19","article-title":"Comparative plasma pharmacokinetics of ceftriaxone and ertapenem in normoalbuminemia, hypoalbuminemia, and albumin replacement in a sheep model","volume":"64","author":"Dhanani","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae270","article-title":"Antifungals in patients with extracorporeal membrane oxygenation: clinical implications","volume":"11","author":"Kriegl","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026031804265805000_ofag093-B31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/s13054-020-03397-1","article-title":"Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study","volume":"24","author":"K\u00fchn","year":"2020","journal-title":"Crit Care"},{"key":"2026031804265805000_ofag093-B32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jointm.2023.12.007","article-title":"Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: a narrative review","volume":"4","author":"Roger","year":"2024","journal-title":"J Intensive Med"},{"key":"2026031804265805000_ofag093-B33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1086\/514505","article-title":"Antimicrobial dosing in obese patients","volume":"25","author":"Wurtz","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2026031804265805000_ofag093-B34","doi-asserted-by":"crossref","first-page":"e0171923","DOI":"10.1128\/aac.01719-23","article-title":"Updated antimicrobial dosing recommendations for obese patients","volume":"68","author":"Castro-Balado","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jcpt.12200","article-title":"Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review","volume":"39","author":"Polso","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"2026031804265805000_ofag093-B36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/0091270004269562","article-title":"The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects","volume":"45","author":"Dvorchik","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B37","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/phar.1298","article-title":"Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States","volume":"33","author":"Bookstaver","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2026031804265805000_ofag093-B38","first-page":"2049936118820230","article-title":"Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight","volume":"6","author":"Fox","year":"2019","journal-title":"Ther Adv Infect Dis"},{"key":"2026031804265805000_ofag093-B39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/phar.2769","article-title":"Comprehensive guidance for antibiotic dosing in obese adults: 2022 update","volume":"43","author":"Meng","year":"2023","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2026031804265805000_ofag093-B40","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1093\/jac\/dkaa368","article-title":"Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav","volume":"75","author":"Mellon","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B41","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/jac\/dkaa312","article-title":"Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function","volume":"75","author":"Smit","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/AAC.05710-11","article-title":"Pharmacokinetics of doxycycline in adults with cystic fibrosis","volume":"56","author":"Beringer","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B43","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.49.12.5013-5017.2005","article-title":"Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis","volume":"49","author":"Beringer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B44","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.chest.2018.06.002","article-title":"Pharmacokinetics of continuous infusion beta-lactams in the treatment of acute pulmonary exacerbations in adult patients with cystic fibrosis","volume":"154","author":"Hong","year":"2018","journal-title":"Chest"},{"key":"2026031804265805000_ofag093-B45","first-page":"655","article-title":"Impact of patient-specific aminoglycoside monitoring for treatment of pediatric cystic fibrosis pulmonary exacerbations","volume":"27","author":"Hemmann","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2026031804265805000_ofag093-B46","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1600-6143.2011.03754.x","article-title":"Delayed graft function in the kidney transplant","volume":"11","author":"Siedlecki","year":"2011","journal-title":"Am J Transplant"},{"key":"2026031804265805000_ofag093-B47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/psp4.12593","article-title":"Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients","volume":"10","author":"Prohn","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026031804265805000_ofag093-B48","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1128\/AAC.00424-16","article-title":"Pharmacokinetics of posaconazole suspension in lung transplant patients with and without cystic fibrosis","volume":"60","author":"Zhang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B49","doi-asserted-by":"crossref","first-page":"511.e1","DOI":"10.1016\/j.jtct.2022.05.030","article-title":"Voriconazole in hematopoietic stem cell transplantation and cellular therapies: real-world usage and therapeutic level attainment at a major transplantation center","volume":"28","author":"Lindsay","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026031804265805000_ofag093-B50","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/jac\/dkae006","article-title":"Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients","volume":"79","author":"Selby","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B51","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00228-016-2057-6","article-title":"Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients","volume":"72","author":"Vanstraelen","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/17425255.2016.1139575","article-title":"Pharmacokinetics of drugs in adult living donor liver transplant patients: regulatory factors and observations based on studies in animals and humans","volume":"12","author":"Li","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026031804265805000_ofag093-B53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2165\/00003088-198916030-00002","article-title":"Clinical pharmacokinetics in organ transplant patients","volume":"16","author":"Venkataramanan","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/dkh268","article-title":"Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients","volume":"54","author":"Buijk","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B55","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/bcp.13595","article-title":"Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients","volume":"84","author":"Lin","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B56","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40262-017-0606-5","article-title":"Population pharmacokinetics and dosing considerations for the use of linezolid in overweight and obese adult patients","volume":"57","author":"Cojutti","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B57","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40268-021-00365-0","article-title":"Effects of letermovir and\/or methylprednisolone coadministration on voriconazole pharmacokinetics in hematopoietic stem cell transplantation: a population pharmacokinetic study","volume":"21","author":"Suetsugu","year":"2021","journal-title":"Drugs R D"},{"key":"2026031804265805000_ofag093-B58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/cpt.382","article-title":"Pregnancy-related pharmacokinetic changes","volume":"100","author":"Tasnif","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2026031804265805000_ofag093-B59","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40262-017-0539-z","article-title":"Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy","volume":"56","author":"Dallmann","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B60","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.clpt.6100126","article-title":"Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies","volume":"81","author":"Andrew","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2026031804265805000_ofag093-B61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40262-023-01211-z","article-title":"Pharmacokinetics and target attainment of antimicrobial drugs throughout pregnancy: part I\u2014penicillins","volume":"62","author":"Hesse","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fphar.2014.00065","article-title":"Physiologic and pharmacokinetic changes in pregnancy","volume":"5","author":"Costantine","year":"2014","journal-title":"Front Pharmacol"},{"key":"2026031804265805000_ofag093-B63","doi-asserted-by":"crossref","first-page":"e1002160","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review","volume":"13","author":"Pariente","year":"2016","journal-title":"PLoS Med"},{"key":"2026031804265805000_ofag093-B64","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.1992.tb04092.x","article-title":"The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women","volume":"33","author":"Heikkil\u00e4","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B65","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach","volume":"44","author":"Anderson","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B66","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40262-023-01226-6","article-title":"The pharmacokinetics and target attainment of antimicrobial drugs throughout pregnancy: part III non-penicillin and non-cephalosporin drugs","volume":"62","author":"Groen","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0305-4179(86)90152-X","article-title":"Studies on systemic absorption of tobramycin in polyethylene glycol ointment applied to wounds of burn patients","volume":"12","author":"Aoyama","year":"1986","journal-title":"Burns Incl Therm Inj"},{"key":"2026031804265805000_ofag093-B68","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00000637-199112000-00008","article-title":"Penetration of antibiotics through omiderm in vitro and on split-thickness skin grafts in burn patients","volume":"27","author":"Russavage","year":"1991","journal-title":"Ann Plast Surg"},{"key":"2026031804265805000_ofag093-B69","first-page":"414","article-title":"Liposome delivery of aminoglycosides in burn wounds","volume":"174","author":"Price","year":"1992","journal-title":"Surg Gynecol Obstet"},{"key":"2026031804265805000_ofag093-B70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2017.09.019","article-title":"The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: an appraisal utilizing antibiotics","volume":"123","author":"Udy","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"2026031804265805000_ofag093-B71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/sur.2020.375","article-title":"Pharmacokinetics and pharmacodynamics of antimicrobial agents in burn patients","volume":"22","author":"Pruskowski","year":"2021","journal-title":"Surg Infect (Larchmt)"},{"key":"2026031804265805000_ofag093-B72","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/antibiotics11050618","article-title":"Comparison of piperacillin and tazobactam pharmacokinetics in critically ill patients with trauma or with burn","volume":"11","author":"Selig","year":"2022","journal-title":"Antibiotics"},{"key":"2026031804265805000_ofag093-B73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jac\/44.3.319","article-title":"Pharmacokinetics of antibiotics in burn patients","volume":"44","author":"Weinbren","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B74","doi-asserted-by":"crossref","first-page":"e21245","DOI":"10.1371\/journal.pone.0021245","article-title":"Long-term persistence of the pathophysiologic response to severe burn injury","volume":"6","author":"Jeschke","year":"2011","journal-title":"PLoS One"},{"key":"2026031804265805000_ofag093-B75","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/jac\/dkm265","article-title":"Dose-related selection of fluoroquinolone-resistant Escherichia coli","volume":"60","author":"Olofsson","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B76","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/AAC.42.3.521","article-title":"Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy","volume":"42","author":"Thomas","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B77","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1060028021991943","article-title":"High-dose daptomycin and clinical applications","volume":"55","author":"Jones","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2026031804265805000_ofag093-B78","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/antibiotics9070393","article-title":"Augmented renal clearance and how to augment antibiotic dosing","volume":"9","author":"Chen","year":"2020","journal-title":"Antibiotics"},{"key":"2026031804265805000_ofag093-B79","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10096-019-03769-8","article-title":"Diagnostic and medical needs for therapeutic drug monitoring of antibiotics","volume":"39","author":"Mabilat","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026031804265805000_ofag093-B80","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026031804265805000_ofag093-B81","first-page":"81","article-title":"Estimating renal function for drug dosing decisions","volume":"32","author":"Jones","year":"2011","journal-title":"Clin Biochem Rev"},{"key":"2026031804265805000_ofag093-B82","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2215\/CJN.05150418","article-title":"Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens","volume":"13","author":"Roberts","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026031804265805000_ofag093-B83","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/cid\/ciy790","article-title":"Renal dosing of antibiotics: are we jumping the gun?","volume":"68","author":"Crass","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026031804265805000_ofag093-B84","doi-asserted-by":"crossref","first-page":"e2019209","DOI":"10.1001\/jamanetworkopen.2020.19209","article-title":"Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement","volume":"3","author":"Ostermann","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026031804265805000_ofag093-B85","first-page":"100970","article-title":"A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients","volume":"40","author":"Heffernan","year":"2021","journal-title":"Anaesth Crit Care Pain Med"},{"key":"2026031804265805000_ofag093-B86","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/17425255.2021.1902985","article-title":"The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients","volume":"17","author":"Fiore","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026031804265805000_ofag093-B87","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4161\/org.7.1.13997","article-title":"Renal replacement therapy review: past, present and future","volume":"7","author":"Fleming","year":"2011","journal-title":"Organogenesis"},{"key":"2026031804265805000_ofag093-B88","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00134-022-06847-2","article-title":"Machines that help machines to help patients: optimising antimicrobial dosing in patients receiving extracorporeal membrane oxygenation and renal replacement therapy using dosing software","volume":"48","author":"Roberts","year":"2022","journal-title":"Intensive Care Med"},{"key":"2026031804265805000_ofag093-B89","doi-asserted-by":"crossref","first-page":"e00583-19.","DOI":"10.1128\/AAC.00583-19","article-title":"A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy","volume":"63","author":"Pistolesi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B90","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae451","article-title":"Validation of cefiderocol package insert dosing recommendation for patients receiving continuous renal replacement therapy: a prospective multicenter pharmacokinetic study","volume":"11","author":"Fouad","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026031804265805000_ofag093-B91","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40262-021-01086-y","article-title":"Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy","volume":"61","author":"Wenzler","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B92","doi-asserted-by":"crossref","first-page":"106603","DOI":"10.1016\/j.ijantimicag.2022.106603","article-title":"Pharmacokinetics and time above the MIC exposure of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (ECMO)","volume":"60","author":"Kois","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026031804265805000_ofag093-B93","doi-asserted-by":"crossref","first-page":"e0063321","DOI":"10.1128\/Spectrum.00633-21","article-title":"Population pharmacokinetics and dosing optimization of piperacillin-tazobactam in critically ill patients on extracorporeal membrane oxygenation and the influence of concomitant renal replacement therapy","volume":"9","author":"Hahn","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2026031804265805000_ofag093-B94","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.3390\/jcm11236898","article-title":"Pharmacokinetics, pharmacodynamics, and dosing considerations of novel \u03b2-lactams and \u03b2-lactam\/\u03b2-lactamase inhibitors in critically ill adult patients: focus on obesity, augmented renal clearance, renal replacement therapies, and extracorporeal membrane oxygenation","volume":"11","author":"Bakdach","year":"2022","journal-title":"J Clin Med"},{"key":"2026031804265805000_ofag093-B95","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s15010-019-01352-z","article-title":"Therapeutic drug monitoring-guided continuous infusion of piperacillin\/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience","volume":"47","author":"Richter","year":"2019","journal-title":"Infection"},{"key":"2026031804265805000_ofag093-B96","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/antibiotics10111311","article-title":"Assessment of a PK\/PD target of continuous infusion beta-lactams useful for preventing microbiological failure and\/or resistance development in critically ill patients affected by documented gram-negative infections","volume":"10","author":"Gatti","year":"2021","journal-title":"Antibiotics"},{"key":"2026031804265805000_ofag093-B97","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3390\/antibiotics12081289","article-title":"\u03b2-Lactam pharmacokinetic\/pharmacodynamic target attainment in intensive care unit patients: a prospective, observational, cohort study","volume":"12","author":"Guilhaumou","year":"2023","journal-title":"Antibiotics"},{"key":"2026031804265805000_ofag093-B98","doi-asserted-by":"crossref","first-page":"e01008-18","DOI":"10.1128\/AAC.01008-18","article-title":"Pharmacodynamic target attainment for cefepime, meropenem, and piperacillin-tazobactam using a pharmacokinetic\/pharmacodynamic-based dosing calculator in critically ill patients","volume":"62","author":"Heil","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B99","first-page":"1","article-title":"National Health and Nutrition Examination Survey 2017\u2013March 2020 prepandemic data files\u2014development of files and prevalence estimates for selected health outcomes","author":"Stierman","year":"2021","journal-title":"Natl Health Stat Report"},{"key":"2026031804265805000_ofag093-B100","volume-title":"Defining adult overweight and obesity","author":"Centers for Disease Control and Prevention (CDC)","year":"2022"},{"key":"2026031804265805000_ofag093-B101","volume-title":"Demystifying drug dosing in obese patients","author":"Shank","year":"2015"},{"key":"2026031804265805000_ofag093-B102","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM198208053070607","article-title":"Intramuscular or intralipomatous injections?","volume":"307","author":"Cockshott","year":"1982","journal-title":"N Engl J Med"},{"key":"2026031804265805000_ofag093-B103","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1177\/1060028013503110","article-title":"Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis","volume":"47","author":"Haselden","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2026031804265805000_ofag093-B104","doi-asserted-by":"crossref","first-page":"e0084522","DOI":"10.1128\/aac.00845-22","article-title":"Population pharmacokinetics\/pharmacodynamics and clinical outcomes of meropenem in critically ill patients","volume":"66","author":"Boonpeng","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B105","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00134-010-2105-0","article-title":"Optimization of meropenem dosage in the critically ill population based on renal function","volume":"37","author":"Crandon","year":"2011","journal-title":"Intensive Care Med"},{"key":"2026031804265805000_ofag093-B106","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1128\/AAC.02010-15","article-title":"Prospective, controlled study of acyclovir pharmacokinetics in obese patients","volume":"60","author":"Turner","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B107","doi-asserted-by":"crossref","first-page":"ofz121","DOI":"10.1093\/ofid\/ofz121","article-title":"Impact of obesity on acyclovir-induced nephrotoxicity","volume":"6","author":"Barber","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026031804265805000_ofag093-B108","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/0897190016642689","article-title":"Dosing practices of intravenous acyclovir for herpes encephalitis in obesity: results of a pharmacist survey","volume":"30","author":"Wong","year":"2017","journal-title":"J Pharm Pract"},{"key":"2026031804265805000_ofag093-B109","doi-asserted-by":"crossref","first-page":"415.e1","DOI":"10.1016\/j.ajog.2015.05.030","article-title":"Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women","volume":"213","author":"Swank","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"2026031804265805000_ofag093-B110","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/jcph.851","article-title":"Population pharmacokinetics of cefazolin in serum and adipose tissue from overweight and obese women undergoing cesarean delivery","volume":"57","author":"Grupper","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B111","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2146\/ajhp120568","article-title":"Clinical practice guidelines for antimicrobial prophylaxis in surgery","volume":"70","author":"Bratzler","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"2026031804265805000_ofag093-B112","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1007\/s11695-022-06196-5","article-title":"Prophylactic cefazolin dosing in obesity\u2014a systematic review","volume":"32","author":"Coates","year":"2022","journal-title":"Obes Surg"},{"key":"2026031804265805000_ofag093-B113","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1586\/14787210.2014.912942","article-title":"Dosing of antibacterial agents in obese adults: does one size fit all?","volume":"12","author":"Payne","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026031804265805000_ofag093-B114","doi-asserted-by":"crossref","first-page":"e01619-20","DOI":"10.1128\/AAC.01619-20","article-title":"Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections","volume":"65","author":"Blackman","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B115","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/jcm9041067","article-title":"Linezolid concentrations in plasma and subcutaneous tissue are reduced in obese patients, resulting in a higher risk of underdosing in critically ill patients: a controlled clinical pharmacokinetic study","volume":"9","author":"Simon","year":"2020","journal-title":"J Clin Med"},{"key":"2026031804265805000_ofag093-B116","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/jac\/dkv126","article-title":"Pharmacokinetics of high dosage of linezolid in two morbidly obese patients","volume":"70","author":"Corcione","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B117","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/QCO.0b013e328359a4c1","article-title":"Dosing of antibiotics in obesity","volume":"25","author":"Janson","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"2026031804265805000_ofag093-B118","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/phar.2023","article-title":"Comprehensive guidance for antibiotic dosing in obese adults","volume":"37","author":"Meng","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2026031804265805000_ofag093-B119","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/dky500","article-title":"Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia","volume":"74","author":"Xie","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1586\/14787210.2016.1128822","article-title":"Dosing of antifungal agents in obese people","volume":"14","author":"Payne","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026031804265805000_ofag093-B121","first-page":"1178","article-title":"Therapeutic drug monitoring and use of an adjusted body weight strategy for high-dose voriconazole therapy","volume":"72","author":"Richards","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B122","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/jac\/dks312","article-title":"Evaluation of the effect of obesity on voriconazole serum concentrations","volume":"67","author":"Koselke","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B123","doi-asserted-by":"crossref","first-page":"e0246020","DOI":"10.1128\/AAC.02460-20","article-title":"Evaluation of total body weight versus adjusted body weight voriconazole dosing in obese patients","volume":"65","author":"Diller","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B124","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/phar.1156","article-title":"Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review","volume":"33","author":"Davies-Vorbrodt","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2026031804265805000_ofag093-B125","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jcf.2017.10.010","article-title":"Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis","volume":"17","author":"Barsky","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2026031804265805000_ofag093-B126"},{"key":"2026031804265805000_ofag093-B127","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jbcr\/irac138","article-title":"Burn injury and augmented renal clearance: a case for optimized piperacillin-tazobactam dosing","volume":"44","author":"Torian","year":"2023","journal-title":"J Burn Care Res"},{"key":"2026031804265805000_ofag093-B128","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.clinthera.2016.08.001","article-title":"Intravenous antibiotic and antifungal agent pharmacokinetic-pharmacodynamic dosing in adults with severe burn injury","volume":"38","author":"Cota","year":"2016","journal-title":"Clin Ther"},{"key":"2026031804265805000_ofag093-B129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jac\/45.3.337","article-title":"Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries","volume":"45","author":"Varela","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B130","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/AAC.40.5.1153","article-title":"Ciprofloxacin pharmacokinetics in burn patients","volume":"40","author":"Garrelts","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B131","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s002280050666","article-title":"Clinical pharmacokinetics of ciprofloxacin in patients with major burns","volume":"55","author":"Lesne-Hulin","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B132","doi-asserted-by":"crossref","first-page":"ofab212","DOI":"10.1093\/ofid\/ofab212","article-title":"Effect of obesity on clinical failure of patients treated with \u03b2-lactams","volume":"8","author":"Pinner","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026031804265805000_ofag093-B133","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1089\/sur.2014.198","article-title":"Vancomycin-associated nephrotoxicity: the obesity factor","volume":"16","author":"Davies","year":"2015","journal-title":"Surg Infect (Larchmt)"},{"key":"2026031804265805000_ofag093-B134","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1086\/673982","article-title":"Identifying targets for antimicrobial stewardship in children's hospitals","volume":"34","author":"Gerber","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026031804265805000_ofag093-B135","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1513\/AnnalsATS.201401-034OI","article-title":"Is there a role for antimicrobial stewardship in cystic fibrosis?","volume":"11","author":"Waters","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2026031804265805000_ofag093-B136","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40262-020-00970-3","article-title":"Antibiotics in adult cystic fibrosis patients: a review of population pharmacokinetic analyses","volume":"60","author":"El Hassani","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B137","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-020-00981-0","article-title":"Pharmacokinetic and pharmacodynamic optimization of antibiotic therapy in cystic fibrosis patients: current evidences, gaps in knowledge and future directions","volume":"60","author":"Magr\u00e9ault","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B138","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/17425255.2021.1836157","article-title":"The pharmacokinetics of antibiotics in cystic fibrosis","volume":"17","author":"Akkerman-Nijland","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026031804265805000_ofag093-B139","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/jcm11030649","article-title":"Intestinal inflammation and alterations in the gut microbiota in cystic fibrosis: a review of the current evidence, pathophysiology and future directions","volume":"11","author":"Tam","year":"2022","journal-title":"J Clin Med"},{"key":"2026031804265805000_ofag093-B140","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.01797-10","article-title":"Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B141","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ppul.24537","article-title":"State of the art in cystic fibrosis pharmacology-optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti\u2013methicillin-resistant Staphylococcus aureus (MRSA) antibiotics","volume":"55","author":"Epps","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2026031804265805000_ofag093-B142","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ppul.22757","article-title":"Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary","volume":"48","author":"Zobell","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2026031804265805000_ofag093-B143","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ppul.26190","article-title":"Retrospective review of vancomycin monitoring via trough only versus two-point estimated area under the curve in pediatric and adult patients with cystic fibrosis","volume":"58","author":"Mitchell","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026031804265805000_ofag093-B144","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jac\/dkt300","article-title":"Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin\/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations","volume":"69","author":"Butterfield","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/ajhp\/zxz011","article-title":"Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis","volume":"76","author":"Davis","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"2026031804265805000_ofag093-B146","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1128\/AAC.01566-16","article-title":"Population pharmacokinetics and safety of ceftolozane-tazobactam in adult cystic fibrosis patients admitted with acute pulmonary exacerbation","volume":"60","author":"Monogue","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B147","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026031804265805000_ofag093-B148","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B149","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3390\/pharmaceutics14122667","article-title":"Dissolution and absorption of inhaled drug particles in the lungs","volume":"14","author":"Eedara","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026031804265805000_ofag093-B150","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/ppul.24511","article-title":"Off-label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis","volume":"54","author":"McKinzie","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2026031804265805000_ofag093-B151","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/jpids\/piac061","article-title":"Drugs, drugs, drugs: current treatment paradigms in cystic fibrosis airway infections","volume":"11","author":"Cogen","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026031804265805000_ofag093-B152","article-title":"The changing landscape of cystic fibrosis clinical trials. Applied Clinical Trials","author":"Cvetkovich-Muntanola"},{"key":"2026031804265805000_ofag093-B153","doi-asserted-by":"crossref","first-page":"105280","DOI":"10.1016\/j.ejps.2020.105280","article-title":"Impact of gastrointestinal physiology on drug absorption in special populations\u2014an UNGAP review","volume":"147","author":"Stillhart","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"2026031804265805000_ofag093-B154","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/bcp.14261","article-title":"Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients","volume":"86","author":"Labriffe","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B155","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1128\/AAC.00504-10","article-title":"Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients","volume":"54","author":"Han","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B156","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40262-020-00982-z","article-title":"A systematic review of the clinical pharmacokinetics, pharmacodynamics and toxicodynamics of ganciclovir\/valganciclovir in allogeneic haematopoietic stem cell transplant patients","volume":"60","author":"Selby","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B157","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","article-title":"Population pharmacokinetic modelling and Bayesian estimation of tacrolimus exposure: is this clinically useful for dosage prediction yet?","volume":"55","author":"Brooks","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B158","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/jcph.1118","article-title":"Tacrolimus population pharmacokinetics and multiple CYP3A5 genotypes in black and white renal transplant recipients","volume":"58","author":"Campagne","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B159","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.semnuclmed.2017.07.002","article-title":"Peri- and postsurgical evaluations of renal transplant","volume":"47","author":"Erbas","year":"2017","journal-title":"Semin Nucl Med"},{"key":"2026031804265805000_ofag093-B160","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.transproceed.2005.02.052","article-title":"Similar impact of slow and delayed graft function on renal allograft outcome and function","volume":"37","author":"Rodrigo","year":"2005","journal-title":"Transplant Proc"},{"key":"2026031804265805000_ofag093-B161","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/ndt\/gfl103","article-title":"Reduced graft function (with or without dialysis) vs immediate graft function\u2014a comparison of long-term renal allograft survival","volume":"21","author":"Johnston","year":"2006","journal-title":"Nephrol Dialysis Transplant"},{"key":"2026031804265805000_ofag093-B162","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12882-017-0553-2","article-title":"Renal association clinical practice guideline in post-operative care in the kidney transplant recipient","volume":"18","author":"Baker","year":"2017","journal-title":"BMC Nephrol"},{"key":"2026031804265805000_ofag093-B163","doi-asserted-by":"crossref","first-page":"151227","DOI":"10.1016\/j.semperi.2020.151227","article-title":"Pharmacokinetic studies in pregnancy","volume":"44","author":"Avram","year":"2020","journal-title":"Semin Perinatol"},{"key":"2026031804265805000_ofag093-B164","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FTD.0000000000001039","article-title":"Optimizing therapeutic drug monitoring in pregnant women: a critical literature review","volume":"45","author":"Moreira","year":"2023","journal-title":"Ther Drug Monit"},{"key":"2026031804265805000_ofag093-B165","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMe1901525","article-title":"Needed: antimicrobial development","volume":"380","author":"Cox","year":"2019","journal-title":"N Engl J Med"},{"key":"2026031804265805000_ofag093-B166","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026031804265805000_ofag093-B167","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2026031804265805000_ofag093-B168","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/jnci\/djae018","article-title":"Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005\u20132020","volume":"116","author":"Choradia","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026031804265805000_ofag093-B169","volume-title":"Exposure\u2013response relationships\u2014study design, data analysis, and regulatory applications","author":"US Food and Drug Administration (FDA)","year":"2003"},{"key":"2026031804265805000_ofag093-B170","volume-title":"Qualified infectious disease product designation questions and answers","author":"Center for Drug Evaluation and Research","year":"2021"},{"key":"2026031804265805000_ofag093-B171","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2026031804265805000_ofag093-B172","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B173","volume-title":"Office of Infectious Diseases Research Activities","author":"Center for Drug Evaluation and Research","year":"2023"},{"key":"2026031804265805000_ofag093-B174","volume-title":"Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling","author":"Center for Drug Evaluation and Research","year":"2020"},{"key":"2026031804265805000_ofag093-B175","volume-title":"SIDP position on incentives to support antimicrobial drug development","author":"Bohn","year":"2024"},{"key":"2026031804265805000_ofag093-B176"},{"key":"2026031804265805000_ofag093-B177","doi-asserted-by":"crossref","first-page":"e00605-19","DOI":"10.1128\/AAC.00605-19","article-title":"Reappraisal of linezolid dosing in renal impairment to improve safety","volume":"63","author":"Crass","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031804265805000_ofag093-B178","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s13054-021-03773-5","article-title":"Ceftolozane\/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial","volume":"25","author":"Shorr","year":"2021","journal-title":"Crit Care"},{"key":"2026031804265805000_ofag093-B179","doi-asserted-by":"crossref","first-page":"e040210","DOI":"10.1136\/bmjopen-2020-040210","article-title":"Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)","volume":"11","author":"Bitterman","year":"2021","journal-title":"BMJ Open"},{"key":"2026031804265805000_ofag093-B180","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1177\/0091270011415979","article-title":"Use of an in vitro model of renal replacement therapy systems to estimate extracorporeal drug removal","volume":"52","author":"Churchwell","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"2026031804265805000_ofag093-B181","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/antibiotics14010092","article-title":"PK\/PD-guided strategies for appropriate antibiotic use in the era of antimicrobial resistance","volume":"14","author":"Onita","year":"2025","journal-title":"Antibiotics"},{"key":"2026031804265805000_ofag093-B182","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/jac\/dkaf199","article-title":"Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm","volume":"80","author":"Koenig","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B183","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2013.01.020","article-title":"All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials","volume":"41","author":"McGovern","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2026031804265805000_ofag093-B184","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026031804265805000_ofag093-B185","first-page":"152","article-title":"Safety of extended interval tobramycin in cystic fibrosis patients less than 6 years old","volume":"23","author":"Arends","year":"2018","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2026031804265805000_ofag093-B186","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"key":"2026031804265805000_ofag093-B187","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12879-020-4781-x","article-title":"The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial","volume":"20","author":"Abdulla","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2026031804265805000_ofag093-B188","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/jac\/dkaa359","article-title":"Early therapeutic monitoring of \u03b2-lactams and associated therapy outcomes in critically ill patients","volume":"75","author":"Al-Shaer","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B189","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031804265805000_ofag093-B190","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections [manuscript published online ahead of print 7 August 2024]","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026031804265805000_ofag093-B191","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026031804265805000_ofag093-B192","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1060028019865873","article-title":"Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update","volume":"54","author":"Hoff","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2026031804265805000_ofag093-B193","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/jac\/dkaf177","article-title":"An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy","volume":"80","author":"McGrath","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026031804265805000_ofag093-B194","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"2026031804265805000_ofag093-B195","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s40265-021-01557-3","article-title":"Pharmacokinetics of commonly used antimicrobials in critically ill adults during extracorporeal membrane oxygenation: a systematic review","volume":"81","author":"Duceppe","year":"2021","journal-title":"Drugs"},{"key":"2026031804265805000_ofag093-B196","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/MCC.0000000000001187","article-title":"Antibiotic dose optimisation in the critically ill: targets, evidence and future strategies","volume":"30","author":"Dyer","year":"2024","journal-title":"Curr Opin Crit Care"},{"key":"2026031804265805000_ofag093-B197","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13054-024-05101-z","article-title":"A narrative review on antimicrobial dosing in adult critically ill patients on extracorporeal membrane oxygenation","volume":"28","author":"Kim","year":"2024","journal-title":"Crit Care"},{"key":"2026031804265805000_ofag093-B198"},{"key":"2026031804265805000_ofag093-B199","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S1473-3099(25)00155-0","article-title":"The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustments","volume":"25","author":"M\u00e4rtson","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026031804265805000_ofag093-B200","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1093\/infdis\/jiae451","article-title":"Population pharmacokinetic modeling of cefepime, meropenem, and piperacillin-tazobactam in patients with cystic fibrosis","volume":"231","author":"Rolsma","year":"2025","journal-title":"J Infect Dis"},{"key":"2026031804265805000_ofag093-B201","doi-asserted-by":"crossref","first-page":"151221","DOI":"10.1016\/j.semperi.2020.151221","article-title":"Drugs in pregnancy: pharmacologic and physiologic changes that affect clinical care","volume":"44","author":"Pinheiro","year":"2020","journal-title":"Semin Perinatol"},{"key":"2026031804265805000_ofag093-B202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/phar.70010","article-title":"A review of antibiotic safety in pregnancy\u20142025 update","volume":"45","author":"Nguyen","year":"2025","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2026031804265805000_ofag093-B203","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/00003088-200847100-00002","article-title":"Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients","volume":"47","author":"Blanchet","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"2026031804265805000_ofag093-B204","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.bbadis.2017.02.019","article-title":"The biochemical alterations underlying post-burn hypermetabolism","volume":"1863","author":"Auger","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag093\/67206560\/ofag093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag093\/67206560\/ofag093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag093\/67206560\/ofag093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:27:32Z","timestamp":1773822452000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag093\/8504001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":204,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag093","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"ofag093"}}